# Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study

> **NCT06211868** · — · RECRUITING · sponsor: **National University Hospital, Singapore** · enrollment: 3000 (estimated)

## Conditions studied

- Cardiovascular Diseases
- Metabolic Syndrome
- Non-Alcoholic Fatty Liver Disease

## Interventions

- **BEHAVIORAL:** Digital wearable and AI-human symbiotic lifestyle intervention

## Key facts

- **NCT ID:** NCT06211868
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-01
- **Primary completion:** 2029-09-01
- **Final completion:** 2030-09-01
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2024-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06211868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06211868, "Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06211868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*